FDA Approves First Therapy for Patients with Lung and Thyroi
U.S. FDA approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers – in patients whose tumors have an alteration in a specific gene (RET or “rearranged during transfection”).

Specifically, the cancers that Retevmo is approved to treat include:
• Non-small cell lung cancer (NSCLC) that has spread in adults,
• Advanced medullary thyroid cancer (MTC) or MTC that has spread, in patients 12 and older who require systemic therapy (a treatment option that spreads across the entire body, is not targeted), and
• Advanced RET fusion-positive thyroid cancer in those age 12 and older that requires systemic therapy that has stopped responding to radioactive iodine therapy or is not appropriate for radioactive iodine therapy

Retevmo can cause serious side effects including hepatotoxicity (liver damage or injury), elevated blood pressure, QT prolongation (the heart muscle takes longer than normal to recharge between beats), bleeding, and allergic reactions.

The FDA granted approval of Retevmo to Loxo Oncology, Inc., a subsidiary of Eli Lilly and Company.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-lung-and-thyroid-cancers-certain-genetic-mutation-or-fusion
Dr. S●●●●y M●●●●●●●●i and 1 others like this1 share